drugset / Trial / NCT00711542

Effects of Intracoronary Progenitor Cell Therapy on Coronary Flow Reserve After Acute MI

NCT00711542 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Coronary flow reserve is an important measure of the integrity of the coronary microcirculation. Moreover, impaired coronary flow reserve is a predictor of future cardiovascular events and poor prognosis in patients after acute myocardial infarction. After acute myocardial infarction, coronary flow reserve remains significantly reduced. A previous randomized, double-blind Placebo-controlled trial (REPAIR-AMI) demonstrated complete normalization of coronary flow reserve after intracoronary application of autologous bone marrow-derived progenitor cells (but no effect in the placebo group) in patients with ST segment elevation myocardial infarction. The current study is planned to extend these findings to patients with Non-ST segment elevation myocardial infarction, since these patients have an equally reduced outcome.

Timeline

Start
2008-09
Primary completion
2014-12
Completion
2015-12

Outcome

Outcome not reported

Stopped (Enrollment): “Slow recruitment”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator autologous bone marrow-derived progenitor cells Cell therapy — Other